Summary: Harmony Biosciences reported strong second-quarter results and advancements in its pitolisant high-dose (HD) development program, aiming for a PDUFA date in 2028. The company highlighted revenue growth driven by Wakix and continued progress across its sleep/wake disorder … [Read more...]